KR20130112880A - 다중불포화 장쇄 케톤을 사용한 류마티스성 관절염 치료법 - Google Patents

다중불포화 장쇄 케톤을 사용한 류마티스성 관절염 치료법 Download PDF

Info

Publication number
KR20130112880A
KR20130112880A KR1020137008287A KR20137008287A KR20130112880A KR 20130112880 A KR20130112880 A KR 20130112880A KR 1020137008287 A KR1020137008287 A KR 1020137008287A KR 20137008287 A KR20137008287 A KR 20137008287A KR 20130112880 A KR20130112880 A KR 20130112880A
Authority
KR
South Korea
Prior art keywords
formula
group
compound
compounds
linking group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020137008287A
Other languages
English (en)
Korean (ko)
Inventor
포이에르헴 아스트리드 줄럼스트뢰
베리트 요한센
Original Assignee
아벡신 에이에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아벡신 에이에스 filed Critical 아벡신 에이에스
Publication of KR20130112880A publication Critical patent/KR20130112880A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/22—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
    • C07C69/92—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring with etherified hydroxyl groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020137008287A 2010-09-02 2011-09-01 다중불포화 장쇄 케톤을 사용한 류마티스성 관절염 치료법 Abandoned KR20130112880A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1014633.0A GB201014633D0 (en) 2010-09-02 2010-09-02 Rheumatoid arthritis treatment
GB1014633.0 2010-09-02
PCT/EP2011/065123 WO2012028688A1 (en) 2010-09-02 2011-09-01 Rheumatoid arthritis treatment using polyunsaturated long chain ketones

Publications (1)

Publication Number Publication Date
KR20130112880A true KR20130112880A (ko) 2013-10-14

Family

ID=43013608

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137008287A Abandoned KR20130112880A (ko) 2010-09-02 2011-09-01 다중불포화 장쇄 케톤을 사용한 류마티스성 관절염 치료법

Country Status (10)

Country Link
US (1) US9682930B2 (cg-RX-API-DMAC7.html)
EP (1) EP2611432A1 (cg-RX-API-DMAC7.html)
JP (2) JP6082347B2 (cg-RX-API-DMAC7.html)
KR (1) KR20130112880A (cg-RX-API-DMAC7.html)
CN (2) CN109893518A (cg-RX-API-DMAC7.html)
AU (1) AU2011298340B2 (cg-RX-API-DMAC7.html)
CA (1) CA2810102A1 (cg-RX-API-DMAC7.html)
GB (1) GB201014633D0 (cg-RX-API-DMAC7.html)
IL (1) IL224963A (cg-RX-API-DMAC7.html)
WO (1) WO2012028688A1 (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8778398B2 (en) 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
MX391660B (es) 2010-03-24 2025-03-21 Jazz Pharmaceuticals Inc Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas
GB201205394D0 (en) 2012-03-27 2012-05-09 Adlens Ltd Improvements in or relating to deformable non-round membrane assemblies
GB201221329D0 (en) 2012-11-27 2013-01-09 Avexxin As Dermatitis treatment
GB201313238D0 (en) 2013-07-24 2013-09-04 Avexxin As Process for the preparation of a polyunsaturated ketone compound
GB201409363D0 (en) * 2014-05-27 2014-07-09 Avexxin As Skin cancer treatment
GB201501144D0 (en) 2015-01-23 2015-03-11 Avexxin As Process for the preparation of a polyunsaturated ketone compound
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
GB201604316D0 (en) 2016-03-14 2016-04-27 Avexxin As Combination therapy
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
CA3037582A1 (en) 2016-09-21 2018-03-29 Avexxin As Pharmaceutical composition
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
JP7305562B2 (ja) * 2017-06-16 2023-07-10 アヴェクシン エーエス 線維性疾患の治療のための組成物および方法
BR112021006027A2 (pt) 2018-11-19 2021-06-29 Jazz Pharmaceuticals Ireland Limited formulações de fármaco resistente a álcool
BR112021013766A2 (pt) 2019-03-01 2021-09-21 Flamel Ireland Limited Composições de gama-hidroxibutirato com farmacocinética melhorada no estado alimentado
GB201910644D0 (en) 2019-07-25 2019-09-11 Coegin Pharma As Cancer Treatment
TW202139986A (zh) 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 治療原發性嗜睡症之方法
US20210311022A1 (en) * 2020-03-27 2021-10-07 Organogenesis, Inc. Methods, kits and compositions for characterizing an anti-inflammatory response of a product
US12582622B2 (en) 2020-10-08 2026-03-24 Jazz Pharmaceuticals Ireland Limited Sodium oxybate to treat idiopathic hypersomnia
IL305969A (en) * 2021-03-23 2023-11-01 Organogenesis Inc Methods kits and compositions for characterizing an anti-inflammatory response of a product
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
CN121038779A (zh) 2023-02-03 2025-11-28 特瑞斯制药公司 每晚一次的低钠羟丁酸盐组合物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670465A (en) * 1986-05-21 1987-06-02 Syntex (U.S.A.) Inc. Arachidonic acid analogs
JPH0987176A (ja) 1995-09-26 1997-03-31 Shiseido Co Ltd 糸球体腎炎抑制剤
JPH09268153A (ja) 1996-04-02 1997-10-14 Sagami Chem Res Center トリフルオロメチルケトン誘導体及びホスホリパーゼa2阻害剤
US6262119B1 (en) * 1996-04-12 2001-07-17 Peptide Technology Limited Methods of treating immunopathologies using polyunsaturated fatty acids
EP1140791A2 (en) 1997-09-23 2001-10-10 Bristol-Myers Squibb Company Selective cpla 2 inhibitors
US6107334A (en) 1998-02-23 2000-08-22 Wake Forest University Dietary control of arachidonic acid metabolism
US7605149B1 (en) 1998-07-13 2009-10-20 University Of South Florida Modulation of the phospholipase A2 pathway as a therapeutic
US6031014A (en) 1998-12-08 2000-02-29 Crivello; James V. Initiator compositions and methods for their synthesis and use
DE60032774D1 (de) 1999-07-19 2007-02-15 Lilly Co Eli Spla2 inhibitoren
WO2002060535A1 (en) * 2001-01-31 2002-08-08 Leff Alan R Method of treating inflammatory conditions by inhibiting cytosolic phospholipase a¿2?
EP1243524A3 (en) 2001-03-16 2004-04-07 Pfizer Products Inc. Pharmaceutical kit for oxygen-sensitive drugs
US7101875B2 (en) * 2001-12-03 2006-09-05 Wyeth Methods for treating arthritic disorders
GB0202002D0 (en) * 2002-01-29 2002-03-13 Leiv Eiriksson Nyotek A S Use
MY131170A (en) 2002-03-28 2007-07-31 Nissan Chemical Ind Ltd Therapeutic agent for glomerular disease
US20040111957A1 (en) 2002-12-13 2004-06-17 Filippini Brian B. Water blended fuel composition
WO2006106438A2 (en) * 2005-01-11 2006-10-12 Evolva Sa Modulators of ppar activity
US20060246115A1 (en) * 2005-03-04 2006-11-02 Ricardo Rueda Nutritional products for ameliorating symptoms of rheumatoid arthritis
EP2114397A4 (en) 2006-12-20 2013-06-12 Medwell Lab Ltd NEW CONJUGATES OF MULTIPLE UNSATURATED FATTY ACIDS WITH AMINES AND ITS THERAPEUTIC USES
NZ552238A (en) 2006-12-20 2009-07-31 Seperex Nutritionals Ltd An extract
EP2207543A2 (en) * 2007-09-14 2010-07-21 Resolvyx Pharmaceuticals, Inc. Omega-3 fatty acids, hydroxy polyunsaturated fatty acids, lipoxin compounds, or oxylipin compounds for treating autoimmune diseases or inhibiting immune function
WO2009061208A1 (en) 2007-11-09 2009-05-14 Pronova Biopharma Norge As Lipid compounds for use in cosmetic products, as food supplement or as a medicament
US8211947B2 (en) * 2008-01-28 2012-07-03 Guillermo Selman-Housein Sosa Composition and method for treating and preventing musculoskeletal and connective tissue disorders
EP2147910A1 (en) 2008-07-15 2010-01-27 Pronova BioPharma Norge AS Novel lipid compounds
KR101783817B1 (ko) * 2009-05-08 2017-10-23 프로노바 바이오파마 너지 에이에스 심혈관 질병, 대사 질병, 및 염증성 질환 분야관련 질병의 치료를 위한 다중 불포화 지방산
GB0909643D0 (en) * 2009-06-04 2009-07-22 Avexxin As Glomerulonephritis treatment
WO2011097276A1 (en) * 2010-02-02 2011-08-11 Martek Biosciences Corporation Methods and compositions for treating arthritis with docosahexaenoic acid

Also Published As

Publication number Publication date
AU2011298340A1 (en) 2013-03-28
EP2611432A1 (en) 2013-07-10
CN103249408A (zh) 2013-08-14
IL224963A (en) 2017-09-28
JP6082347B2 (ja) 2017-02-15
US9682930B2 (en) 2017-06-20
CA2810102A1 (en) 2012-03-08
JP2017075148A (ja) 2017-04-20
US20130245127A1 (en) 2013-09-19
GB201014633D0 (en) 2010-10-13
WO2012028688A1 (en) 2012-03-08
AU2011298340B2 (en) 2014-09-25
JP2013540713A (ja) 2013-11-07
CN109893518A (zh) 2019-06-18

Similar Documents

Publication Publication Date Title
JP6082347B2 (ja) ポリ不飽和長鎖ケトンを用いるリウマチ性関節炎の治療
CN103751194B (zh) 用于治疗病症的方法和组合物
JPH07509460A (ja) 金属タンパク質加水分解酵素阻害剤であるヒドロキサム酸誘導体
KR19980064024A (ko) 약학 조성물
CN110946854A (zh) 超纯的四氢大麻酚-11-羧酸
CN101434517A (zh) 治疗免疫疾病的新的1,2-二苯基乙烯衍生物
ITMI962385A1 (it) Diaril-ciclometilenpirazoli farmacologicamente attivi procedimento per prepararli e composizioni farmaceutiche che li contengono
US20140128418A1 (en) Pyrazole derivatives, preparation method thereof, and composition for preventing and treating osteoporosis containing same
NO175148B (no) Fremgangsmåte for fremstilling av et indomethacinsalt av et toverdig metall valgt fra kobber, sink, kobolt og nikkel
EP0357403A2 (en) Substituted beta-diketones
US12545643B2 (en) 3,5-diaminobenzoic acid compound, and Pin1 inhibitor and therapeutic agent for inflammatory diseases using same
JPS61275274A (ja) 1,3−ジチオ−ル−2−イリデン誘導体及びその用途
CN101389633B (zh) 有机化合物
EP3475264A1 (en) Prostaglandin e synthase inhibitors and methods for utilizing the same
EP1507523A1 (en) Cinnamic acid dimers, their preparation and the use thereof for treating neurodegenerative disease
JP2012514594A (ja) 薬理学的に活性な薬剤としてのチエノピリジン
KR20220012198A (ko) 벤조퓨란계 n-아실하이드라존 유도체를 포함하는 항염증 조성물
JPH02172920A (ja) 抗潰瘍剤
EP0177927A1 (en) 3-Hydroxybenzo[b]thiophene-2-sulfide derivatives as specific-5-lipoxygenase inhibitors
CN111303161B (zh) 嘧啶并氮杂环类化合物及其用途
WO2005037759A1 (ja) 新規フェノール誘導体およびそれらを有効成分とする抗トリパノソーマ予防・治療剤
WO2019232665A1 (zh) 一类具有抗癌活性的硫代吲嗪类化合物及其衍生物
US20210052537A1 (en) Colitis ameliorating agent
WO2022238741A1 (en) Coumarin compounds and a process for preparation thereof
KR20110088623A (ko) 퓨마릴 옥사졸리디논 유도체를 함유하는 염증질환 또는 면역질환의 예방 및 치료용 약학 조성물

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20130401

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20160825

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170517

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20171114

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20170517

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20171114

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20170714

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20160825

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20180312

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20180213

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20171114

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20170714

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20170517

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20160825

X601 Decision of rejection after re-examination
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20180514

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20180312

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Patent event date: 20171114

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20191104

Appeal identifier: 2018101002086

Request date: 20180514

J301 Trial decision

Free format text: TRIAL NUMBER: 2018101002086; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20180514

Effective date: 20191104

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20191104

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20180514

Decision date: 20191104

Appeal identifier: 2018101002086

PS0901 Examination by remand of revocation
S901 Examination by remand of revocation
GRNO Decision to grant (after opposition)
PS0701 Decision of registration after remand of revocation

Patent event date: 20191202

Patent event code: PS07012S01D

Comment text: Decision to Grant Registration

Patent event date: 20191104

Patent event code: PS07011S01I

Comment text: Notice of Trial Decision (Remand of Revocation)

NORF Unpaid initial registration fee
PC1904 Unpaid initial registration fee